Telomir Pharmaceuticals has revealed promising preclinical data for its leading drug candidate, Telomir-1, which shows potential to reverse cellular decline in human cell lines.

These findings support further research into Telomir-1's possible applications for conditions such as autism spectrum disorder, spasmodic dysphonia, and other age-related or degenerative diseases.

In addition to its regenerative effects, Telomir-1 protected cells from metal-induced toxicity, including iron and copper, and helped maintain cell viability under various stress conditions.

The drug also improved mitochondrial function, reduced oxidative stress, and restored calcium balance in stressed cells, highlighting its potential to combat cellular aging and degeneration.

While these results are still preclinical, they establish a mechanistic foundation for broader therapeutic exploration in regenerative medicine.

Looking ahead, Telomir plans to advance Telomir-1 toward human clinical trials, with an IND application targeted for filing and first-in-human dosing expected in the first half of 2026.